PDF(Pubmed)
Abstract：
UNASSIGNED:
UNASSIGNED: This multicenter study aimed to retrospectively evaluate the impact of high boost simultaneous integrated boost (SIB) to pathologic lymph nodes compared to Sequential boost (Seq) in patients with locally advanced cervical cancer (LACC).
UNASSIGNED: 97 patients with pelvic and/or para-aortic (PAo) node-positive LACC treated by definitive chemoradiation were included. Two groups were analyzed: Sequential boost group and simultaneous integrated boost (SIB) group. Endpoints were Distant Recurrence Free Survival (DRFS), Recurrence Free Survival (RFS), Overall Survival (OS), locoregional pelvic and PAo control and toxicities.
UNASSIGNED: 3-years DRFS in SIB and Seq groups was 65% and 31% respectively (log-rank p < 0.001). 3-years RFS was 58% and 26% respectively (log-rank p = 0.009). DRFS prognostic factors in multivariable analysis were SIB, PAo involvement and maximum pelvic node diameter ≥ 2cm. Adenocarcinoma histology and absence of brachytherapy tended to be prognostic factors. SIB provided the best pelvic control at first imaging with 97%. There was no significant difference in terms of toxicities between groups.
UNASSIGNED: Nodal SIB seems to be unavoidable in the treatment of node-positive LACC. It provides the best DRFS, RFS and pelvic control without additional toxicity, with a shortened treatment duration.
UNASSIGNED: This multicenter study aimed to retrospectively evaluate the impact of high boost simultaneous integrated boost (SIB) to pathologic lymph nodes compared to Sequential boost (Seq) in patients with locally advanced cervical cancer (LACC).
UNASSIGNED: 97 patients with pelvic and/or para-aortic (PAo) node-positive LACC treated by definitive chemoradiation were included. Two groups were analyzed: Sequential boost group and simultaneous integrated boost (SIB) group. Endpoints were Distant Recurrence Free Survival (DRFS), Recurrence Free Survival (RFS), Overall Survival (OS), locoregional pelvic and PAo control and toxicities.
UNASSIGNED: 3-years DRFS in SIB and Seq groups was 65% and 31% respectively (log-rank p < 0.001). 3-years RFS was 58% and 26% respectively (log-rank p = 0.009). DRFS prognostic factors in multivariable analysis were SIB, PAo involvement and maximum pelvic node diameter ≥ 2cm. Adenocarcinoma histology and absence of brachytherapy tended to be prognostic factors. SIB provided the best pelvic control at first imaging with 97%. There was no significant difference in terms of toxicities between groups.
UNASSIGNED: Nodal SIB seems to be unavoidable in the treatment of node-positive LACC. It provides the best DRFS, RFS and pelvic control without additional toxicity, with a shortened treatment duration.
摘要：
■
■这项多中心研究旨在回顾性评估在局部晚期宫颈癌（LACC）患者中，与序贯增强（Seq）相比，高增强同时整合增强（SIB）对病理淋巴结的影响。
■97例盆腔和/或主动脉旁（PAo）淋巴结阳性LACC患者接受确定性放化疗治疗。分析两组：序贯加强组和同时整合加强（SIB）组。终点是远程复发无生存（DRFS），复发免费生存（RFS），总生存率（OS），局部骨盆和PAo控制和毒性。
■SIB组和Seq组的3年DRFS分别为65％和31％（对数秩p<0.001）。3年RFS分别为58%和26%(log-rankp=0.009)。多变量分析的DRFS预后因素为SIB，PAo受累，最大盆腔淋巴结直径≥2cm。腺癌组织学和近距离放射治疗的缺乏往往是预后因素。SIB在首次成像时提供了最佳的骨盆控制，占97％。两组之间的毒性没有显着差异。
■节点SIB在节点阳性LACC的治疗中似乎是不可避免的。它提供了最好的DRFS，RFS和盆腔控制无额外毒性，缩短治疗时间。
■这项多中心研究旨在回顾性评估在局部晚期宫颈癌（LACC）患者中，与序贯增强（Seq）相比，高增强同时整合增强（SIB）对病理淋巴结的影响。
■97例盆腔和/或主动脉旁（PAo）淋巴结阳性LACC患者接受确定性放化疗治疗。分析两组：序贯加强组和同时整合加强（SIB）组。终点是远程复发无生存（DRFS），复发免费生存（RFS），总生存率（OS），局部骨盆和PAo控制和毒性。
■SIB组和Seq组的3年DRFS分别为65％和31％（对数秩p<0.001）。3年RFS分别为58%和26%(log-rankp=0.009)。多变量分析的DRFS预后因素为SIB，PAo受累，最大盆腔淋巴结直径≥2cm。腺癌组织学和近距离放射治疗的缺乏往往是预后因素。SIB在首次成像时提供了最佳的骨盆控制，占97％。两组之间的毒性没有显着差异。
■节点SIB在节点阳性LACC的治疗中似乎是不可避免的。它提供了最好的DRFS，RFS和盆腔控制无额外毒性，缩短治疗时间。
